Treating blood or blood products with compounds which have a mustard, azirdinium or aziridine group and a nucleic acid binding group
AssigneeCerus Corporation
InventorsDavid Cook, Susan Wollowitz, Aileen Nerio
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Claims78
An in vitro method of inactivating a pathogen in mammalian blood or a mammalian blood product comprising:
- (a) contacting in vitro mammalian blood or a mammalian blood product, with a pathogen inactivating amount of a first compound that has a nucleic acid binding ligand and a moiety selected from the group consisting of a mustard group, an aziridinium, and an aziridine, which when incubated with the blood or blood product results in the inactivation of at least 1 log of a pathogen present in the blood or blood product, if any,
- (b) and recovering the pathogen inactivated blood or blood product, wherein the recovered blood or blood product has substantially the same biological activity such that it is suitable for therapeutic use in a mammal,
- wherein the first compound has a greater inactivation efficiency against R17 than a second compound containing a mustard group, aziridinium, or aziridine that lacks the nucleic acid binding ligand.
An in vitro method of inactivating a viral, bacterial or protozoan pathogen in mammalian blood or a mammalian blood product comprising:
- (a) contacting in vitro a first composition comprising the mammalian blood or the mammalian blood product, suspected of containing the pathogen, with a pathogen inactivating amount of a compound I that has a nucleic acid binding ligand and a moiety selected from the group consisting of a mustard group, an aziridinium, and an aziridine, wherein compound I has a greater inactivation efficiency against R17 than a compound II containing a mustard group, an aziridinium, or an aziridine that lacks the nucleic acid binding ligand when incubated with a second composition comprising mammalian blood or a mammalian blood product, and wherein the pathogen inactivating amount results in the inactivation of at least 1 log of a pathogen present in the first composition comprising the blood or blood product, if any,
- (b) and recovering the pathogen inactivated mammalian blood or mammalian blood product, wherein the recovered blood or blood product has substantially the same biological activity such that it is suitable for therapeutic use in a mammal.
An in vitro method of inactivating a pathogen in mammalian blood or a mammalian blood product comprising:
- (a) contacting in vitro mammalian blood or a mammalian blood product, with a pathogen inactivating amount of a first compound that has a chemical group which binds nucleic acid non-covalently by a mode selected from the group consisting of intercalating, minor groove binding, major groove binding, phosphate backbone binding, and sequence specific binding and that has a moiety selected from the group consisting of a mustard group, an aziridinium, and an aziridine, wherein the pathogen inactivating amount results in the inactivation of at least 1 log of a pathogen present in the blood or blood product, if any,
- (b) and recovering the pathogen inactivated blood or blood product, wherein the recovered blood or blood product has substantially the same biological activity such that it is suitable for therapeutic use in a mammal, wherein the first compound has a greater inactivation efficiency against R17 than a second compound containing a mustard group, an aziridinium, or an aziridine that lacks the mode for binding nucleic acid non-covalently.
An in vitro method of inactivating a viral, bacterial or protozoan pathogen in mammalian blood or a mammalian blood product comprising:
- (a) contacting in vitro a first composition comprising the mammalian blood or the mammalian blood product, suspected of containing the pathogen, with a pathogen inactivating amount of a compound I that has a chemical group which binds nucleic acid non-covalently by a mode selected from the group consisting of intercalating, minor groove binding, major groove binding, phosphate backbone binding, and sequence specific binding and has a moiety selected from the group consisting of a mustard group, an aziridinium, and an aziridine, wherein compound I has a greater inactivation efficiency against R17 than a compound II containing a mustard group, an aziridinium, or an aziridine that lacks the mode for binding nucleic acid non-covalently when incubated with a second composition comprising mammalian blood or a mammalian blood product, and wherein the pathogen inactivating amount results in the inactivation of at least 1 log of a pathogen present in the first composition comprising the blood or blood product, if any,
- (b) and recovering the pathogen inactivated mammalian blood or mammalian blood product, wherein the recovered blood or blood product has substantially the same biological activity such that it is suitable for therapeutic use in a mammal.
Dependencies are inferred from the claim text.